SAREPTA THERAPEUTICS, INC. Severance Costs (Deprecated 2013-01-31)
SAREPTA THERAPEUTICS, INC. (SRPT) reported Severance Costs (Deprecated 2013-01-31) of $201.00 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts · last filed 2013-05-09
- SAREPTA THERAPEUTICS, INC. severance costs (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $201.00K.
- SAREPTA THERAPEUTICS, INC. severance costs (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $249.00K.
- SAREPTA THERAPEUTICS, INC. severance costs (deprecated 2013-01-31) for the quarter ending 2012-09-30 was $493.00K.
- SAREPTA THERAPEUTICS, INC. severance costs (deprecated 2013-01-31) for fiscal 2012 was $828.00K, a 161.20% increase from fiscal 2011.
- SAREPTA THERAPEUTICS, INC. severance costs (deprecated 2013-01-31) for fiscal 2011 was $317.00K.
| Period end | Severance Costs (Deprecated 2013-01-31) 3 month | Severance Costs (Deprecated 2013-01-31) 6 month | Severance Costs (Deprecated 2013-01-31) 9 month | Severance Costs (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2013-03-31 | $201.00K 10-Q · filed 2013-05-09 | $450.00K derived: sum of 2 quarters · filed 2013-05-09 | $943.00K derived: sum of 3 quarters · filed 2013-05-09 | |
| 2012-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $742.00K derived: sum of 2 quarters · filed 2013-03-15 | $828.00K 10-K · filed 2013-03-15 | |
| 2012-09-30 | $493.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $579.00K 10-Q · filed 2012-11-07 | ||
| 2012-06-30 | $86.00K 10-Q · filed 2012-08-07 | |||
| 2011-12-31 | $317.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |